Absci Corporation (ABSI) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by. My name is Duncan, and I will be your conference operator for today. I would like to welcome you to Absci first quarter twenty twenty six business update. All lines have been placed on mute to prevent any background noise. And after the speakers' remarks, there will be a question and answer session. Now I'd like to turn over the conference over to Alex Kang. Please go ahead. Thank you. Earlier today, Absci released financial and operating results for the quarter ended 03/31/2026. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an email to investorsabsci dot com. An archived webcast of this call will be available for replay on Absci's Investor Relations website at investors.absci.com for at least ninety days after this call. Joining me today are Sean McLean, Absci's Founder and CEO Zach Sonison, Chief Financial Officer and Chief Business Officer and Ronci Somerotny, Chief Medical Officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward looking statements. These include statements regarding the development and clinical progress of our pipeline programs, including ABS201, the design, enrollment, product, and timelines of our ongoing Phase onetwo ahead line trial of ABS21 for enterogenic alopecia, anticipated timing of interim proof of concept data readout for ABS21 in the second half of twenty twenty six, the potential advancement of ABS201...